Lexaria Bioscience (LEXX) Stock Price, News & Analysis

Company Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Key Stats

• Today's Range: $2.60 to $2.85
• 50-Day Range: $2.75 to $3.91
• 52-Week Range: $1.08 to $6.85
• Volume: 164,391 shs
• Average Volume: 277,712 shs
• Market Capitalization: $34.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Lexaria Bioscience Stock Analysis - MarketRank™

Lexaria Bioscience scored higher than 48% of companies evaluated by MarketBeat, and ranked 603rd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lexaria Bioscience has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.42) to ($0.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexaria Bioscience is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexaria Bioscience is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexaria Bioscience has a P/B Ratio of 8.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.13% of the float of Lexaria Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Lexaria Bioscience has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lexaria Bioscience has recently decreased by 2.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexaria Bioscience does not currently pay a dividend.

Dividend Growth

Lexaria Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.13% of the float of Lexaria Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Lexaria Bioscience has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lexaria Bioscience has recently decreased by 2.02%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexaria Bioscience insiders have sold 105.03% more of their company's stock than they have bought. Specifically, they have bought $5,008.00 in company stock and sold $10,268.00 in company stock.

Percentage Held by Insiders

Only 7.61% of the stock of Lexaria Bioscience is held by insiders.

Percentage Held by Institutions

Only 13.06% of the stock of Lexaria Bioscience is held by institutions.

LEXX Stock Analysis - Frequently Asked Questions

How have LEXX shares performed this year?

Lexaria Bioscience's stock was trading at $1.25 at the beginning of the year. Since then, LEXX shares have increased by 116.0% and is now trading at $2.70.
View the best growth stocks for 2024 here.

How do I buy shares of Lexaria Bioscience?

Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR).

Company Calendar

• Today: 10/23/2024
• Next Earnings (Estimated): 11/19/2024
• Fiscal Year End: 8/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LEXX
• CUSIP: N/A
• CIK: 1348362
• Web: www.lexariabioscience.com
• Phone: (250) 765-6424
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +307.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,660,000.00
• Net Margins: N/A
• Pretax Margin: -1,292.04%
• Return on Equity: -88.39%
• Return on Assets: -84.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 58.27
• Quick Ratio: 58.27

Sales & Book Value

• Annual Sales: $411,019.00
• Price / Sales: 84.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.33 per share
• Price / Book: 8.18

Miscellaneous

• Outstanding Shares: 12,886,000
• Free Float: 14,607,000
• Market Cap: $34.79 million
• Optionable: Not Optionable
• Beta: 0.97